Who is sponsoring NCT00712101?

NCT00712101 is sponsored by University of Leipzig.

What drugs are being tested in NCT00712101?

Interventions in NCT00712101: abciximab intracoronary, abciximab intravenously.

What condition does NCT00712101 study?

NCT00712101 studies ST-elevation Myocardial Infarction.

Is NCT00712101 still recruiting?

NCT00712101 is currently completed. Last updated 19 April 2011.

Last reviewed 2011-04-19 · How we verify

NCT00712101: AIDA STEMI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Randomized Controlled Clinical Study to Compare Abciximab-bolus i.v. Versus i.c. in Primary PCI in Patients With Acute ST-elevation Myocardial Infarction

Completed Phase 3 Last updated 19 April 2011

What this trial tests

Phase 3 trial testing abciximab intracoronary in ST-elevation Myocardial Infarction in 1,912 participants. Completed in 1 April 2011.

Timeline

1 July 2008

Primary endpoint
1 April 2011

1 April 2011

Quick facts

Lead sponsor	University of Leipzig
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,912
Start date	1 July 2008
Primary completion	1 April 2011
Estimated completion	1 April 2011
Sites	11 locations across Germany

Drugs / interventions tested

abciximab intracoronary — full drug profile →
abciximab intravenously — full drug profile →

Conditions studied

ST-elevation Myocardial Infarction — all drugs for ST-elevation Myocardial Infarction →

Sponsor

University of Leipzig

Who can join

18 and older, any sex, with ST-elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Combined clinical endpoint: death, reinfarction, new congestive heart failure
Time frame: 90 days

Sponsor's own description

The purpose of this study is to examine whether intracoronary abciximab bolus application with subsequent 12 hour intravenous infusion in addition to primary percutaneous coronary intervention is beneficial for patients with STEMI in comparison to standard i.v. bolus application with respect to 90-day mortality, reinfarction and new congestive heart failure.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction.
Eitel I, de Waha S, Wöhrle J, Fuernau G, et al · · 2014 · cited 294× · PMID 25236513 · DOI 10.1016/j.jacc.2014.06.1194
Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.
Thiele H, Wöhrle J, Hambrecht R, Rittger H, et al · · 2012 · cited 163× · PMID 22357109 · DOI 10.1016/s0140-6736(11)61872-2
Cardiac Magnetic Resonance Myocardial Feature Tracking for Optimized Prediction of Cardiovascular Events Following Myocardial Infarction.
Eitel I, Stiermaier T, Lange T, Rommel KP, et al · · 2018 · cited 160× · PMID 29454776 · DOI 10.1016/j.jcmg.2017.11.034
Left Atrial Function with MRI Enables Prediction of Cardiovascular Events after Myocardial Infarction: Insights from the AIDA STEMI and TATORT NSTEMI Trials.
Schuster A, Backhaus SJ, Stiermaier T, Navarra JL, et al · · 2019 · cited 74× · PMID 31526253 · DOI 10.1148/radiol.2019190559
Left Ventricular Thrombus Formation After ST-Segment-Elevation Myocardial Infarction: Insights From a Cardiac Magnetic Resonance Multicenter Study.
Pöss J, Desch S, Eitel C, de Waha S, et al · · 2015 · cited 63× · PMID 26481162 · DOI 10.1161/circimaging.115.003417
The relation between hypointense core, microvascular obstruction and intramyocardial haemorrhage in acute reperfused myocardial infarction assessed by cardiac magnetic resonance imaging.
Kandler D, Lücke C, Grothoff M, Andres C, et al · · 2014 · cited 51× · PMID 25097126 · DOI 10.1007/s00330-014-3318-3
Optimized Prognosis Assessment in ST-Segment-Elevation Myocardial Infarction Using a Cardiac Magnetic Resonance Imaging Risk Score.
Stiermaier T, Jobs A, de Waha S, Fuernau G, et al · · 2017 · cited 42× · PMID 29122844 · DOI 10.1161/circimaging.117.006774
Cardiovascular magnetic resonance-derived left atrioventricular coupling index and major adverse cardiac events in patients following acute myocardial infarction.
Lange T, Backhaus SJ, Schulz A, Evertz R, et al · · 2023 · cited 40× · PMID 37046343 · DOI 10.1186/s12968-023-00929-w

Verify or expand the search:

Other University of Leipzig trials

Trials by the same sponsor.

NCT07155564 — Validation of Energy Expenditure Measures Study · recruiting
NCT06656832 — Peripheral Drivers of Heart Failure Progression - the Prospective PEDAL-HF Study · NA · not yet recruiting
NCT06526013 — Cholesterol Self-testing in Patients Post Acute Coronary Syndrome · NA · recruiting
NCT06420622 — INDIcators for Clarifying the bAckground of exTreme Obesity in childRen · recruiting
NCT06269263 — Feasibility of Home-based Cardiac Rehabilitation in Patients With Chronic Heart Failure (Pilot-CRHF) · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00712101 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Leipzig
Last refreshed: 19 April 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00712101.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing